These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21965642)

  • 1. The influence of the definition of patient global assessment in assessment of disease activity according to the Disease Activity Score (DAS28) in rheumatoid arthritis.
    Dougados M; Ripert M; Hilliquin P; Fardellone P; Brocq O; Brault Y; Logeart I
    J Rheumatol; 2011 Nov; 38(11):2326-8. PubMed ID: 21965642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
    El Miedany Y; Youssef SS; El Gaafary M
    J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA.
    Keystone E; Freundlich B; Schiff M; Li J; Hooper M
    J Rheumatol; 2009 Mar; 36(3):522-31. PubMed ID: 19228659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-derived joint counts are a potential alternative for determining Disease Activity Score.
    Kavanaugh A; Lee SJ; Weng HH; Chon Y; Huang XY; Lin SL
    J Rheumatol; 2010 May; 37(5):1035-41. PubMed ID: 20156946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results.
    van der Heijde D; Klareskog L; Boers M; Landewé R; Codreanu C; Bolosiu HD; Pedersen R; Fatenejad S;
    Ann Rheum Dis; 2005 Nov; 64(11):1582-7. PubMed ID: 15860509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid reduction in tenosynovitis of the wrist and fingers evaluated by MRI in patients with rheumatoid arthritis after treatment with etanercept.
    Lisbona MP; Maymó J; Perich J; Almirall M; Carbonell J
    Ann Rheum Dis; 2010 Jun; 69(6):1117-22. PubMed ID: 20448287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hand function tests are important and sensitive tools for assessment of treatment response in patients with rheumatoid arthritis.
    Eberhardt K; Sandqvist G; Geborek P
    Scand J Rheumatol; 2008; 37(2):109-12. PubMed ID: 18415767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis.
    Guis S; Balandraud N; Bouvenot J; Auger I; Toussirot E; Wendling D; Mattei JP; Nogueira L; Mugnier B; Legeron P; Landt O; Serre G; Roudier J; Roudier C
    Arthritis Rheum; 2007 Dec; 57(8):1426-30. PubMed ID: 18050183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and ultrasound-based composite disease activity indices in rheumatoid arthritis: results from a multicenter, randomized study.
    Mandl P; Balint PV; Brault Y; Backhaus M; D'Agostino MA; Grassi W; van der Heijde D; de Miguel E; Wakefield RJ; Logeart I; Dougados M
    Arthritis Care Res (Hoboken); 2013 Jun; 65(6):879-87. PubMed ID: 23213004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The impact of therapy with TNF-blockers on health-related quality of life in rheumatoid arthritis patients. A pilot study].
    Abalos Medina GM; Ruiz Villaverde G; Sánchez Cano D; Ruiz Villaverde R; Ramírez Rodrigo J; Raya Álvarez E; Villaverde Gutiérrez C
    Reumatol Clin; 2011; 7(3):167-71. PubMed ID: 21794808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.
    van der Heijde D; Klareskog L; Singh A; Tornero J; Melo-Gomes J; Codreanu C; Pedersen R; Freundlich B; Fatenejad S
    Ann Rheum Dis; 2006 Mar; 65(3):328-34. PubMed ID: 16079172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
    Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
    Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability.
    Baumgartner SW; Fleischmann RM; Moreland LW; Schiff MH; Markenson J; Whitmore JB
    J Rheumatol; 2004 Aug; 31(8):1532-7. PubMed ID: 15290731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does clinical remission lead to normalization of EQ-5D in patients with rheumatoid arthritis and is selection of remission criteria important?
    Linde L; Sørensen J; Østergaard M; Hørslev-Petersen K; Hetland ML
    J Rheumatol; 2010 Feb; 37(2):285-90. PubMed ID: 20080905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simplified versions of the original disease activity score: validation in the BeSt trial.
    Koevoets R; Klarenbeek NB; Güler-Yüksel M; van Oosterhout M; van Krugten MV; Kerstens PJ; Huizinga TW; Dijkmans BA; van der Heijde DM; Allaart CF
    Ann Rheum Dis; 2011 Aug; 70(8):1471-4. PubMed ID: 21551508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC; Chung SJ; Park YB; Lee SK
    Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which variables best predict change in rheumatoid arthritis therapy in daily clinical practice?
    Soubrier M; Zerkak D; Gossec L; Ayral X; Roux C; Dougados M
    J Rheumatol; 2006 Jul; 33(7):1243-6. PubMed ID: 16622906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a patient-based disease activity score in rheumatoid arthritis that can be used in clinical trials and routine practice.
    Choy EH; Khoshaba B; Cooper D; MacGregor A; Scott DL
    Arthritis Rheum; 2008 Feb; 59(2):192-9. PubMed ID: 18240256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease Activity Score 28-ESR bears a similar relationship to treatment decisions across different rheumatologists, but misclassification is too frequent to replace physician judgement.
    Taylor WJ; Harrison AA; Highton J; Chapman P; Stamp L; Dockerty J; McQueen F; Jones PB; Ching D; Porter D; Rajapakse C; Rudge SR; Taylor G; Kumar S; Macedo T; Hoy MS
    Rheumatology (Oxford); 2008 Apr; 47(4):514-8. PubMed ID: 18321947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes.
    Wolfe F; Michaud K; Pincus T; Furst D; Keystone E
    Arthritis Rheum; 2005 Dec; 52(12):3873-9. PubMed ID: 16320335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.